Drugs / JNJ-86974680
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07319871 | Jan 2026 → Jan 2027 expected | prostate neoplasm | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06116786 | Nov 2023 → Apr 2027 expected | non-small cell lung carcinoma | Johnson & Johnson Enterprise Innovation Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNJ-86974680 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06116786 ↗ |
| Action | Inhibit | “JNJ-86974680, an A2a Receptor Antagonist” NCT06116786 ↗ |
| Route | Oral | “JNJ-86974680 will be administered orally.” NCT07319871 ↗ |